title: Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
authors.affiliation: Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds. p.emery@leeds.ac.uk [corrected]
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.forename: R
authors.initials: R
authors.lastname: Van Vollenhoven
authors.forename: M
authors.initials: M
authors.lastname: Ostergaard
authors.forename: E
authors.initials: E
authors.lastname: Choy
authors.forename: B
authors.initials: B
authors.lastname: Combe
authors.forename: W
authors.initials: W
authors.lastname: Graninger
authors.forename: K
authors.initials: K
authors.lastname: Krueger
authors.forename: M
authors.initials: M
authors.lastname: Matucci-Cerinic
authors.forename: F
authors.initials: F
authors.lastname: Navarro
authors.forename: P
authors.initials: P
authors.lastname: van Riel
authors.forename: L
authors.initials: L
authors.lastname: Settas
authors.forename: S
authors.initials: S
authors.lastname: Steinfeld
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha